Results 251 to 260 of about 858,870 (284)
Clinical Pharmacology of Cilazapril [PDF]
Drugs, 1989 In clinical pharmacology studies, cilazapril, after its bioactivation to cilazaprilat, was characterised as a potent, reversible angiotensin converting enzyme (ACE) inhibitor with a terminal half-life of 30 to 50 hours, which is consistent with saturable binding to ACE.
Ulf-W. Wiegand +3 more
openaire +3 more sources
Pharmacology and Clinical Pharmacology of Vigabatrin [PDF]
Journal of Child Neurology, 1991 Vigabatrin is an enzyme-activated, irreversible inhibitor of γ-aminobutyric acid (GABA) aminotransferase, which causes a marked increase in cerebral GABA concentration and a resulting anticonvulsant action. Recovery from its effects requires the synthesis of new enzyme, and this may take several days following a single dose.
openaire +2 more sources
Some of the next articles are maybe not open access.
Related searches:
Related searches:
DeckerMed Surgery, 2020
Critically ill patients often require surgical procedures and therapeutic interventions that produce significant pathophysiologic changes. Drug pharmacology can be greatly altered in this population wherein comorbid diseases, varied organ function, and polypharmacy can produce adverse drug reactions (ADRs).
Eric W. Mueller, Molly Droege
openaire +1 more source
Critically ill patients often require surgical procedures and therapeutic interventions that produce significant pathophysiologic changes. Drug pharmacology can be greatly altered in this population wherein comorbid diseases, varied organ function, and polypharmacy can produce adverse drug reactions (ADRs).
Eric W. Mueller, Molly Droege
openaire +1 more source
Clinical pharmacology of progestins
Minerva Obstetrics and Gynecology, 2022In this paper, we report general pharmacological profile and major biological activities of natural progesterone (P) and progestins. The aim of this article consists of synthesizing the principal aspects of pharmacology and metabolism of P and progestins related to the clinical consequences of their use.We review scientific literature on the topic ...
Capozzi, Anna +2 more
openaire +3 more sources
JAMA: The Journal of the American Medical Association, 1989
The issue of what drug effects to measure, surrogate end points, has been emphasized by two recent clinical trials. Several recent studies have given us new information about why different people react so differently to the same dose of the same medicine.
openaire +5 more sources
The issue of what drug effects to measure, surrogate end points, has been emphasized by two recent clinical trials. Several recent studies have given us new information about why different people react so differently to the same dose of the same medicine.
openaire +5 more sources
Clinical Pharmacology of Inodilators
Journal of Cardiovascular Pharmacology, 1989Recent advances in our knowledge of heart failure have shown that both a central and a peripheral factor are involved in this syndrome. Therefore, the ideal drug should combine the properties of a positive inotropic agent with those of a peripheral vasodilator; many drugs recently introduced into clinical practice have been shown to present both of ...
DEI CAS, Livio +2 more
openaire +4 more sources
Clinical Pharmacology of Lacidipine
Journal of Cardiovascular Pharmacology, 1991The safety and tolerability of lacidipine was assessed in a volunteer population, and its pharmacodynamic and pharmacokinetic profiles evaluated. In normotensive subjects, single oral doses of 3-5 mg of lacidipine produced a dose-related fall in peripheral vascular resistance.
S. T. Hall +4 more
openaire +2 more sources
Rapacuronium: clinical pharmacology
European Journal of Anaesthesiology, 2001The need for a rapid-acting non-depolarizing neuromuscular blocking agent with a short duration of action resulted in the synthesis of rapacuronium. The onset of maximum block with rapacuronium occurs in 60-90 s with doses of 1.5-2.5 mg kg-1 with a duration of clinical relaxation of 15-30 min.
K. C. McCourt, Rajinder K. Mirakhur
openaire +2 more sources
Clinical pharmacology of etoricoxib
Expert Opinion on Drug Metabolism & Toxicology, 2005Etoricoxib is a highly selective COX-2 inhibitor (coxib) approved in Europe for the treatment of osteoarthritis (OA), rheumatoid arthritis and acute gouty arthritis. Etoricoxib is an effective analgesic drug that has shown some improved efficacy versus traditional NSAIDs and it is the only coxib approved for the treatment of acute gouty arthritis ...
CAPONE ML +2 more
openaire +3 more sources